Increased Intestinal Permeability and Decreased Barrier Function: Does It Really Influence the Risk of Inflammation?

Inflammatory Intestinal Diseases

Volumn 1, Issue 3, 2016, Pages 135-145

  Fukui, Hiroshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Acute pancreatitis; Chronic heart failure; Chronic kidney disease; Depression; Endotoxemia; Inflammatory bowel disease; Intestinal permeability; Irritable bowel syndrome; Liver disease

Indexed keywords

C REACTIVE PROTEIN; ENDOTOXIN; FLAGELLIN; IMMUNOGLOBULIN M; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; LIPID A; TIGHT JUNCTION PROTEIN; TOLL LIKE RECEPTOR 3; TOLL LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR;

ACUTE PANCREATITIS; ALCOHOL LIVER DISEASE; ANTIBODY DETECTION; CHOLANGITIS; CHRONIC KIDNEY FAILURE; CYTOKINE STORM; DEPRESSION; DISEASE ASSOCIATION; DYSBIOSIS; FAECALIBACTERIUM; FAECALIBACTERIUM PRAUSNITZII; HEART FAILURE; HUMAN; INFLAMMATORY BOWEL DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INTESTINE EPITHELIUM; INTESTINE FLORA; INTESTINE INFECTION; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; LIVER CIRRHOSIS; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; OBSTRUCTIVE JAUNDICE; PERMEABILITY BARRIER; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; RUMINOCOCCACEAE; RUMINOCOCCUS;

EID: 85041318977     PISSN: 22969403     EISSN: 22969365     Source Type: Journal    
DOI: 10.1159/000447252     Document Type: Review

References (110)

1. Kelly JR, Kennedy PJ, Cryan JF, Dinan TG, Clarke G, Hyland NP: Breaking down the barriers: the gut microbiome, intestinal permeability and stress-related psychiatric disorders. Front Cell Neurosci 2015;9: 392.
2. Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM: Intestinal permeability - a new target for disease prevention and therapy. BMC Gastroenterol 2014;14: 189.
3. Valentini L, Ramminger S, Haas V, Postrach E, Werich M, Fischer A, Koller M, Swidsinski A, Bereswill S, Lochs H, Schulzke JD: Small intestinal permeability in older adults. Physiol Rep 2014;2:e00281.
4. Wyatt J, Oberhuber G, Pongratz S, Puspok A, Moser G, Novacek G, Lochs H, Vogelsang H: Increased gastric and intestinal permeability in patients with Crohn's disease. Am J Gastroenterol 1997;92: 1891-1896.
5. Vivinus-Nebot M, Frin-Mathy G, Bzioueche H, Dainese R, Bernard G, Anty R, Filippi J, Saint-Paul MC, Tulic MK, Verhasselt V, Hebuterne X, Piche T: Functional bowel symptoms in quiescent inflammatory bowel diseases: role of epithelial barrier disruption and low-grade inflammation. Gut 2014;63: 744- 752.
6. Oriishi T, Sata M, Toyonaga A, Sasaki E, Tanikawa K: Evaluation of intestinal permeability in patients with inflammatory bowel disease using lactulose and measuring antibodies to lipid A. Gut 1995;36: 891-896.
7. Buning C, Geissler N, Prager M, Sturm A, Baumgart DC, Buttner J, Buhner S, Haas V, Lochs H: Increased small intestinal permeability in ulcerative colitis: rather genetic than environmental and a risk factor for extensive disease? Inflamm Bowel Dis 2012;18: 1932- 1939.
8. Gerova VA, Stoynov SG, Katsarov DS, Svinarov DA: Increased intestinal permeability in inflammatory bowel diseases assessed by iohexol test. World J Gastroenterol 2011;17: 2211-2215.
9. Petit CS, Barreau F, Besnier L, Gandille P, Riveau B, Chateau D, Roy M, Berrebi D, Svrcek M, Cardot P, Rousset M, Clair C, Thenet S: Requirement of cellular prion protein for intestinal barrier function and mislocalization in patients with inflammatory bowel disease. Gastroenterology 2012;143: 122- 132.e15.
10. Gardiner KR, Halliday MI, Barclay GR, Milne L, Brown D, Stephens S, Maxwell RJ, Rowlands BJ: Significance of systemic endotoxaemia in inflammatory bowel disease. Gut 1995;36: 897-901.
11. Pastor Rojo O, Lopez San Roman A, Albeniz Arbizu E, de la Hera Martinez A, Ripoll Sevillano E, Albillos Martinez A: Serum lipopolysaccharide- binding protein in endotoxemic patients with inflammatory bowel disease. Inflamm Bowel Dis 2007;13: 269-277.
12. Takaishi H, Matsuki T, Nakazawa A, Takada T, Kado S, Asahara T, Kamada N, Sakuraba A, Yajima T, Higuchi H, Inoue N, Ogata H, Iwao Y, Nomoto K, Tanaka R, Hibi T: Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. Int J Med Microbiol 2008;298: 463-472.
13. Pitcher MC, Beatty ER, Cummings JH: The contribution of sulphate reducing bacteria and 5-aminosalicylic acid to faecal sulphide in patients with ulcerative colitis. Gut 2000;46: 64-72.
14. Baars A, Oosting A, Knol J, Garssen J, van Bergenhenegouwen J: The gut microbiota as a therapeutic target in ibd and metabolic disease: a role for the bile acid receptors FXR and TGR5. Microorganisms 2015;3: 641-666.
15. Camilleri M, Lasch K, Zhou W: Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2012;303:G775-G785.
16. Shulman RJ, Jarrett ME, Cain KC, Broussard EK, Heitkemper MM: Associations among gut permeability, inflammatory markers, and symptoms in patients with irritable bowel syndrome. J Gastroenterol 2014;49: 1467- 1476.
17. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M: Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58: 196-201.
18. Bertiaux-Vandaele N, Youmba SB, Belmonte L, Lecleire S, Antonietti M, Gourcerol G, Leroi AM, Dechelotte P, Menard JF, Ducrotte P, Coeffier M: The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011;106: 2165- 2173.
19. Liebregts T, Adam B, Bredack C, Roth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G: Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132: 913- 920.
20. Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, Rossi F, Lo Monte AI, Rizzo AG, Raimondo D: Inflammation in irritable bowel syndrome: myth or new treatment target? World J Gastroenterol 2016;22: 2242-2255.
21. Lee YJ, Park KS: Irritable bowel syndrome: emerging paradigm in pathophysiology. World J Gastroenterol 2014;20: 2456-2469.
22. Ringel Y, Maharshak N: Intestinal microbiota and immune function in the pathogenesis of irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2013;305:G529- G541.
23. Schoepfer AM, Schaffer T, Seibold-Schmid B, Muller S, Seibold F: Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil 2008;20: 1110-1118.
24. Ohman L, Simren M: Intestinal microbiota and its role in irritable bowel syndrome (IBS). Curr Gastroenterol Rep 2013;15: 323.
25. Bjarnason I, Peters TJ, Wise RJ: The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984;1: 179-182.
26. Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S: Leaky gut in alcoholic cirrhosis: a possible mechanism for alcoholinduced liver damage. Am J Gastroenterol 1999;94: 200-207.
27. Leclercq S, Matamoros S, Cani PD, Neyrinck AM, Jamar F, Starkel P, Windey K, Tremaroli V, Backhed F, Verbeke K, de Timary P, Delzenne NM: Intestinal permeability, gut-bacterial dysbiosis, and behavioral markers of alcohol- dependence severity. Proc Natl Acad Sci USA 2014;111:E4485-E4493.
28. Fukui H: Gut-liver axis in liver cirrhosis: how to manage leaky gut and endotoxemia. World J Hepatol 2015;7: 425-442.
29. Parlesak A, Schafer C, Schutz T, Bode JC, Bode C: Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32: 742-747.
30. Keshavarzian A, Fields JZ, Vaeth J, Holmes EW: The differing effects of acute and chronic alcohol on gastric and intestinal permeability. Am J Gastroenterol 1994;89: 2205-2211.
31. Bode JC, Bode C, Heidelbach R, Durr HK, Martini GA: Jejunal microflora in patients with chronic alcohol abuse. Hepatogastroenterology 1984;31: 30-34.
32. Elamin E, Masclee A, Troost F, Pieters HJ, Keszthelyi D, Aleksa K, Dekker J, Jonkers D: Ethanol impairs intestinal barrier function in humans through mitogen activated protein kinase signaling: a combined in vivo and in vitro approach. PLoS One 2014;9:e107421.
33. Kalaitzakis E: Gastrointestinal dysfunction in liver cirrhosis. World J Gastroenterol 2014;20: 14686-14695.
34. Elamin EE, Masclee AA, Dekker J, Jonkers DM: Ethanol metabolism and its effects on the intestinal epithelial barrier. Nutr Rev 2013;71: 483-499.
35. Tang Y, Forsyth CB, Farhadi A, Rangan J, Jakate S, Shaikh M, Banan A, Fields JZ, Keshavarzian A: Nitric oxide-mediated intestinal injury is required for alcohol-induced gut leakiness and liver damage. Alcohol Clin Exp Res 2009;33: 1220-1230.
36. Yan AW, Fouts DE, Brandl J, Starkel P, Torralba M, Schott E, Tsukamoto H, Nelson KE, Brenner DA, Schnabl B: Enteric dysbiosis associated with a mouse model of alcoholic liver disease. Hepatology 2011;53: 96-105.
37. Fujimoto M, Uemura M, Nakatani Y, Tsujita S, Hoppo K, Tamagawa T, Kitano H, Kikukawa M, Ann T, Ishii Y, Kojima H, Sakurai S, Tanaka R, Namisaki T, Noguchi R, Higashino T, Kikuchi E, Nishimura K, Takaya A, Fukui H: Plasma endotoxin and serum cytokine levels in patients with alcoholic hepatitis: relation to severity of liver disturbance. Alcohol Clin Exp Res 2000;24: 48S-54S.
38. Hanck C, Rossol S, Bocker U, Tokus M, Singer MV: Presence of plasma endotoxin is correlated with tumour necrosis factor receptor levels and disease activity in alcoholic cirrhosis. Alcohol Alcohol 1998;33: 606-608.
39. Guo J, Friedman SL: Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 2010;3: 21.
40. Mutlu EA, Gillevet PM, Rangwala H, Sikaroodi M, Naqvi A, Engen PA, Kwasny M, Lau CK, Keshavarzian A: Colonic microbiome is altered in alcoholism. Am J Physiol Gastrointest Liver Physiol 2012;302:G966-G978.
41. Bull-Otterson L, Feng W, Kirpich I, Wang Y, Qin X, Liu Y, Gobejishvili L, Joshi-Barve S, Ayvaz T, Petrosino J, Kong M, Barker D, Mc-Clain C, Barve S: Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of Lactobacillus rhamnosus GG treatment. PLoS One 2013;8:e53028.
42. Wang Y, Kirpich I, Liu Y, Ma Z, Barve S, Mc-Clain CJ, Feng W: Lactobacillus rhamnosus GG treatment potentiates intestinal hypoxiainducible factor, promotes intestinal integrity and ameliorates alcohol-induced liver injury. Am J Pathol 2011;179: 2866-2875.
43. Fukui H: Gut microbiota and host reaction in liver diseases. Microorganisms 2015;3: 759- 791.
44. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Masciana R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A: Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49: 1877-1887.
45. Giorgio V, Miele L, Principessa L, Ferretti F, Villa MP, Negro V, Grieco A, Alisi A, Nobili V: Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Dig Liver Dis 2014;46: 556-560.
46. Alisi A, Manco M, Devito R, Piemonte F, Nobili V: Endotoxin and plasminogen activator inhibitor-1 serum levels associated with nonalcoholic steatohepatitis in children. J Pediatr Gastroenterol Nutr 2010;50: 645-649.
47. Kapil S, Duseja A, Sharma BK, Singla B, Chakraborti A, Das A, Ray P, Dhiman RK, Chawla Y: Small intestinal bacterial overgrowth and toll like receptor signaling in patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 2016;31: 213-221.
48. Sharifnia T, Antoun J, Verriere TG, Suarez G, Wattacheril J, Wilson KT, Peek RM Jr, Abumrad NN, Flynn CR: Hepatic TLR4 signaling in obese NAFLD. Am J Physiol Gastrointest Liver Physiol 2015;309:G270-G278.
49. Gabele E, Dostert K, Hofmann C, Wiest R, Scholmerich J, Hellerbrand C, Obermeier F: DSS induced colitis increases portal LPS levels and enhances hepatic inflammation and fibrogenesis in experimental NASH. J Hepatol 2011;55: 1391-1399.
50. Douhara A, Moriya K, Yoshiji H, Noguchi R, Namisaki T, Kitade M, Kaji K, Aihara Y, Nishimura N, Takeda K, Okura Y, Kawaratani H, Fukui H: Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep 2015;11: 1693-1700.
51. Shanab AA, Scully P, Crosbie O, Buckley M, O'Mahony L, Shanahan F, Gazareen S, Murphy E, Quigley EM: Small intestinal bacterial overgrowth in nonalcoholic steatohepatitis: association with toll-like receptor 4 expression and plasma levels of interleukin 8. Dig Dis Sci 2011;56: 1524-1534.
52. Amar J, Chabo C, Waget A, Klopp P, Vachoux C, Bermudez-Humaran LG, Smirnova N, Berge M, Sulpice T, Lahtinen S, Ouwehand A, Langella P, Rautonen N, Sansonetti PJ, Burcelin R: Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment. EMBO Mol Med 2011;3: 559-572.
53. Ouchi N, Parker JL, Lugus JJ, Walsh K: Adipokines in inflammation and metabolic disease. Nat Rev Immunol 2011;11: 85-97.
54. Pijls KE, Jonkers DM, Elamin EE, Masclee AA, Koek GH: Intestinal epithelial barrier function in liver cirrhosis: an extensive review of the literature. Liver Int 2013;33: 1457-1469.
55. Assimakopoulos SF, Tsamandas AC, Tsiaoussis GI, Karatza E, Triantos C, Vagianos CE, Spiliopoulou I, Kaltezioti V, Charonis A, Nikolopoulou VN, Scopa CD, Thomopoulos KC: Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012;42: 439-446.
56. Bellot P, Frances R, Such J: Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013;33: 31-39.
57. Jun DW, Kim KT, Lee OY, Chae JD, Son BK, Kim SH, Jo YJ, Park YS: Association between small intestinal bacterial overgrowth and peripheral bacterial DNA in cirrhotic patients. Dig Dis Sci 2010;55: 1465-1471.
58. Seki E, Schnabl B: Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012;590: 447-458.
59. Attar BM, George M, Ion-Nedelcu N, Ramadori G, Thiel DH: Disease dependent qualitative and quantitative differences in the inflammatory response to ascites occurring in cirrhotics. World J Hepatol 2014;6: 85-91.
60. Fukui H, Tsujita S, Matsumoto M, Morimura M, Kitano H, Kinoshita K, Kikuchi E, Okamoto Y, Tsujii T: Endotoxin inactivating action of plasma in patients with liver cirrhosis. Liver 1995;15: 104-109.
61. Nakatani Y, Fukui H, Kitano H, Nagamoto I, Tsujimoto T, Kuriyama S, Kikuchi E, Hoppou K, Tsujii T: Endotoxin clearance and its relation to hepatic and renal disturbances in rats with liver cirrhosis. Liver 2001;21: 64-70.
62. Soares JB, Pimentel-Nunes P, Roncon-Albuquerque R, Leite-Moreira A: The role of lipopolysaccharide/ toll-like receptor 4 signaling in chronic liver diseases. Hepatol Int 2010;4: 659-672.
63. Feld JJ, Meddings J, Heathcote EJ: Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci 2006;51: 1607-1613.
64. Floreani A, Baragiotta A, Pizzuti D, Martines D, Cecchetto A, Chiarelli S: Mucosal IgA defect in primary biliary cirrhosis. Am J Gastroenterol 2002;97: 508-510.
65. Zhao J, Zhao S, Zhou G, Liang L, Guo X, Mao P, Zhou X, Wang H, Nan Y, Xu D, Yu J: Altered biliary epithelial cell and monocyte responses to lipopolysaccharide as a TLR ligand in patients with primary biliary cirrhosis. Scand J Gastroenterol 2011;46: 485-494.
66. Wang AP, Migita K, Ito M, Takii Y, Daikoku M, Yokoyama T, Komori A, Nakamura M, Yatsuhashi H, Ishibashi H: Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005;25: 85-91.
67. Haruta I, Hashimoto E, Kato Y, Kikuchi K, Kato H, Yagi J, Uchiyama T, Kobayash M, Shiratori K: Lipoteichoic acid may affect the pathogenesis of bile duct damage in primary biliary cirrhosis. Autoimmunity 2006;39: 129-135.
68. Assimakopoulos SF, Scopa CD, Vagianos CE: Pathophysiology of increased intestinal permeability in obstructive jaundice. World J Gastroenterol 2007;13: 6458-6464.
69. Welsh FK, Ramsden CW, MacLennan K, Sheridan MB, Barclay GR, Guillou PJ, Reynolds JV: Increased intestinal permeability and altered mucosal immunity in cholestatic jaundice. Ann Surg 1998;227: 205-212.
70. Parks RW, Clements WD, Smye MG, Pope C, Rowlands BJ, Diamond T: Intestinal barrier dysfunction in clinical and experimental obstructive jaundice and its reversal by internal biliary drainage. Br J Surg 1996;83: 1345- 1349.
71. Assimakopoulos SF, Vagianos CE, Charonis A, Nikolopoulou VN, Scopa CD: Intestinal failure in obstructive jaundice. World J Gastroenterol 2005;11: 3806-3807.
72. Kimmings AN, van Deventer SJ, Obertop H, Rauws EA, Huibregtse K, Gouma DJ: Endotoxin, cytokines, and endotoxin binding proteins in obstructive jaundice and after preoperative biliary drainage. Gut 2000;46: 725-731.
73. Ljungdahl M, Osterberg J, Ransjo U, Engstrand L, Haglund U: Inflammatory response in patients with malignant obstructive jaundice. Scand J Gastroenterol 2007;42: 94-102.
74. Badger SA, Jones C, McCaigue M, Clements BW, Parks RW, Diamond T, McCallion K, Taylor MA: Cytokine response to portal endotoxaemia and neutrophil stimulation in obstructive jaundice. Eur J Gastroenterol Hepatol 2012;24: 25-32.
75. Assimakopoulos SF, Tsamandas AC, Louvros E, Vagianos CE, Nikolopoulou VN, Thomopoulos KC, Charonis A, Scopa CD: Intestinal epithelial cell proliferation, apoptosis and expression of tight junction proteins in patients with obstructive jaundice. Eur J Clin Invest 2011;41: 117-125.
76. Yang R, Harada T, Li J, Uchiyama T, Han Y, Englert JA, Fink MP: Bile modulates intestinal epithelial barrier function via an extracellular signal related kinase 1/2 dependent mechanism. Intensive Care Med 2005;31: 709-117.
77. Liu H, Li W, Wang X, Li J, Yu W: Early gut mucosal dysfunction in patients with acute pancreatitis. Pancreas 2008;36: 192-196.
78. Rahman SH, Ammori BJ, Holmfield J, Larvin M, McMahon MJ: Intestinal hypoperfusion contributes to gut barrier failure in severe acute pancreatitis. J Gastrointest Surg 2003;7: 26-35; discussion 35-36.
79. Ammori BJ, Leeder PC, King RF, Barclay GR, Martin IG, Larvin M, McMahon MJ: Early increase in intestinal permeability in patients with severe acute pancreatitis: correlation with endotoxemia, organ failure, and mortality. J Gastrointest Surg 1999;3: 252-262.
80. Koh YY, Jeon WK, Cho YK, Kim HJ, Chung WG, Chon CU, Oh TY, Shin JH: The effect of intestinal permeability and endotoxemia on the prognosis of acute pancreatitis. Gut Liver 2012;6: 505-511.
81. Kylanpaa ML, Repo H, Puolakkainen PA: Inflammation and immunosuppression in severe acute pancreatitis. World J Gastroenterol 2010;16: 2867-2872.
82. Deng WS, Zhang J, Ju H, Zheng HM, Wang J, Wang S, Zhang DL: Arpin contributes to bacterial translocation and development of severe acute pancreatitis. World J Gastroenterol 2015;21: 4293-4301.
83. Capurso G, Zerboni G, Signoretti M, Valente R, Stigliano S, Piciucchi M, Delle Fave G: Role of the gut barrier in acute pancreatitis. J Clin Gastroenterol 2012;46(suppl):S46-S51.
84. Tan C, Ling Z, Huang Y, Cao Y, Liu Q, Cai T, Yuan H, Liu C, Li Y, Xu K: Dysbiosis of intestinal microbiota associated with inflammation involved in the progression of acute pancreatitis. Pancreas 2015;44: 868-875.
85. Magnusson M, Magnusson KE, Sundqvist T, Denneberg T: Impaired intestinal barrier function measured by differently sized polyethylene glycols in patients with chronic renal failure. Gut 1991;32: 754-759.
86. Goldstein DA, Horowitz RE, Petit S, Haldimann B, Massry SG: The duodenal mucosa in patients with renal failure: response to 1, 25(OH)2D3. Kidney Int 1981;19: 324-331.
87. Vaziri ND, Dure-Smith B, Miller R, Mirahmadi MK: Pathology of gastrointestinal tract in chronic hemodialysis patients: an autopsy study of 78 cases. Am J Gastroenterol 1985;80: 608-611.
88. Vaziri ND, Goshtasbi N, Yuan J, Jellbauer S, Moradi H, Raffatellu M, Kalantar-Zadeh K: Uremic plasma impairs barrier function and depletes the tight junction protein constituents of intestinal epithelium. Am J Nephrol 2012;36: 438-443.
89. Vaziri ND, Yuan J, Norris K: Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013;37: 1-6.
90. Lau WL, Kalantar-Zadeh K, Vaziri ND: The gut as a source of inflammation in chronic kidney disease. Nephron 2015;130: 92-98.
91. Wang F, Zhang P, Jiang H, Cheng S: Gut bacterial translocation contributes to microinflammation in experimental uremia. Dig Dis Sci 2012;57: 2856-2862.
92. Szeto CC, Kwan BC, Chow KM, Lai KB, Chung KY, Leung CB, Li PK: Endotoxemia is related to systemic inflammation and atherosclerosis in peritoneal dialysis patients. Clin J Am Soc Nephrol 2008;3: 431-436.
93. McIntyre CW, Harrison LE, Eldehni MT, Jefferies HJ, Szeto CC, John SG, Sigrist MK, Burton JO, Hothi D, Korsheed S, Owen PJ, Lai KB, Li PK: Circulating endotoxemia: a novel factor in systemic inflammation and cardiovascular disease in chronic kidney disease. Clin J Am Soc Nephrol 2011;6: 133-141.
94. Feroze U, Kalantar-Zadeh K, Sterling KA, Molnar MZ, Noori N, Benner D, Shah V, Dwivedi R, Becker K, Kovesdy CP, Raj DS: Examining associations of circulating endotoxin with nutritional status, inflammation, and mortality in hemodialysis patients. J Ren Nutr 2012;22: 317-326.
95. Wong J, Piceno YM, Desantis TZ, Pahl M, Andersen GL, Vaziri ND: Expansion of urease- and uricase-containing, indole- and pcresol- forming and contraction of shortchain fatty acid-producing intestinal microbiota in ESRD. Am J Nephrol 2014;39: 230-237.
96. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M, Poole-Wilson P, Volk HD, Lochs H, Anker SD: Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 2007;50: 1561-1569.
97. Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, Verri M, Dioguardi F: Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 2015;4: 220- 227.
98. Niebauer J, Volk HD, Kemp M, Dominguez M, Schumann RR, Rauchhaus M, Poole-Wilson PA, Coats AJ, Anker SD: Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet 1999;353: 1838-1842.
99. Sharma R, Bolger AP, Li W, Davlouros PA, Volk HD, Poole-Wilson PA, Coats AJ, Gatzoulis MA, Anker SD: Elevated circulating levels of inflammatory cytokines and bacterial endotoxin in adults with congenital heart disease. Am J Cardiol 2003;92: 188-193.
100. Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, Kalra PR, Buhner S, Herrmann R, Springer J, Doehner W, von Haehling S, Anker SD, Rauchhaus M: Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol 2012;157: 80-85.
101. Rogler G, Rosano G: The heart and the gut. Eur Heart J 2014;35: 426-430.
102. Maes M, Kubera M, Leunis JC: The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from Gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro Endocrinol Lett 2008;29: 117-124.
103. Berk M, Williams LJ, Jacka FN, O'Neil A, Pasco JA, Moylan S, Allen NB, Stuart AL, Hayley AC, Byrne ML, Maes M: So depression is an inflammatory disease, but where does the inflammation come from? BMC Med 2013;11: 200.
104. Miller AH, Raison CL: The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol 2015;16: 22-34.
105. Brambilla P, Bellani M, Isola M, Bergami A, Marinelli V, Dusi N, Rambaldelli G, Tansella M, Finardi AM, Martino G, Perlini C, Furlan R: Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl Psychiatry 2014;4:e406.
106. Drago A, Crisafulli C, Calabro M, Serretti A: Enrichment pathway analysis. The inflammatory genetic background in bipolar disorder. J Affect Disord 2015;179: 88-94.
107. Mostafavi S, Battle A, Zhu X, Potash JB, et al: Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Mol Psychiatry 2014;19: 1267-1274.
108. Pandey GN, Rizavi HS, Ren X, Fareed J, Hoppensteadt DA, Roberts RC, Conley RR, Dwivedi Y: Proinflammatory cytokines in the prefrontal cortex of teenage suicide victims. J Psychiatr Res 2012;46: 57-63.
109. Pandey GN, Rizavi HS, Ren X, Bhaumik R, Dwivedi Y: Toll-like receptors in the depressed and suicide brain. J Psychiatr Res 2014;53: 62-68.
110. Kanai T, Matsuoka K, Naganuma M, Hayashi A, Hisamatsu T: Diet, microbiota, and inflammatory bowel disease: lessons from Japanese foods. Korean J Intern Med 2014;29: 409-415.